Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2024-01-18 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
迈威生物2024年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement from an extraordinary general meeting of shareholders held on January 18, 2024. It details the meeting attendance, voting results on various company governance-related proposals, and includes a lawyer's witness statement confirming the legality and validity of the meeting and voting process. There is no financial data, no discussion of financial results, no audit information, no earnings data, and no mention of report attachments. The content is focused on the official announcement of voting results from a shareholders meeting. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 3157 characters, which is consistent with a detailed voting results announcement rather than a brief report publication announcement or a full report.
2024-01-18 Chinese
迈威生物第二届监事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution by Maiwei (Shanghai) Biotechnology Co., Ltd. It details the meeting's convening, attendance, and the approval of a proposal regarding the continued use of temporarily idle raised funds for cash management. The document references compliance with relevant laws and stock exchange rules and provides voting results. It does not contain financial statements, audit opinions, or detailed financial data. It is not a full report but an announcement of a board/committee decision. Therefore, it fits best under Board/Management Information (MANG), as it relates to a supervisory board meeting resolution and internal governance matters.
2024-01-18 Chinese
迈威生物关于继续使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Maiwei (Shanghai) Biotechnology Co., Ltd. regarding the continued use of temporarily idle raised funds for cash management. It details the board and supervisory committee approvals, the amount and purpose of the cash management, risk controls, and compliance with regulatory requirements. The document references the approval by the China Securities Regulatory Commission for the initial public offering and the use of raised funds, but it does not contain financial statements or detailed financial performance data. It is a regulatory announcement about the use of capital raised from an IPO, specifically about cash management of idle funds, not a financial report or earnings release. The document length is 3737 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under the category of Capital/Financing Update (CAP), as it concerns the management and use of capital raised by the company.
2024-01-18 Chinese
海通证券股份有限公司关于迈威（上海）生物科技股份有限公司继续使用部分暂时闲置募集资金进行现金管理的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Haitong Securities regarding the continued use of temporarily idle raised funds by Maiwei (Shanghai) Biotechnology Co., Ltd. for cash management. It includes specifics about the amount, purpose, investment products, risk control measures, and approvals by the board and supervisory committee. The document references regulatory guidelines and confirms compliance with relevant laws and listing rules. It is not a brief announcement but a substantive report on the use of raised funds, including financial oversight and risk management. This fits the category of a Capital/Financing Update (CAP), as it concerns the management and use of raised capital funds, not an announcement of a report or a general regulatory filing. The document length is under 5,000 characters but contains detailed content, not just a notice or certification. Therefore, the best classification is CAP with high confidence.
2024-01-18 Chinese
迈威生物首次公开发行战略配售限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the listing and circulation of restricted shares from the company's initial public offering (IPO) strategic placement shares. It details the number of shares becoming freely tradable after the lock-up period, the date of circulation, shareholder commitments, and includes a verification opinion from the sponsoring institution. The document does not contain financial statements or detailed financial performance data but rather informs about the change in share status and circulation. It is a formal notice about share capital changes related to restricted shares becoming tradable. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is short (2305 characters), and it is not a report publication announcement or a certification. Hence, the classification is SHA with high confidence.
2024-01-08 Chinese
海通证券股份有限公司关于迈威（上海）生物科技股份有限公司首次公开发行战略配售限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from Haitong Securities regarding the listing and circulation of restricted shares from the company's initial public offering (IPO) strategic placement. It discusses the unlocking and circulation of restricted shares, the compliance with regulatory requirements, and the fulfillment of shareholder commitments. The document is not a full financial report, earnings release, or management discussion, but rather a formal verification and compliance statement related to share circulation post-IPO. It is a regulatory compliance and verification announcement related to share listing and circulation, fitting best under Regulatory Filings (RNS). The document length is 2522 characters, relatively short and focused on compliance verification rather than a full report or announcement of a report publication.
2024-01-08 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.